268 related articles for article (PubMed ID: 28792505)
1. Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Tseng JC; Narayanan N; Ho G; Groves K; Delaney J; Bao B; Zhang J; Morin J; Kossodo S; Rajopadhye M; Peterson JD
PLoS One; 2017; 12(8):e0182689. PubMed ID: 28792505
[TBL] [Abstract][Full Text] [Related]
2. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
3. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
4. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
5. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J
PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251
[TBL] [Abstract][Full Text] [Related]
7. 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Ambrosini V; Quarta C; Zinzani PL; Nanni C; Fini M; Torricelli P; Giavaresi G; D'Errico-Grigioni A; Malvi D; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Dec; 54(6):689-97. PubMed ID: 20639808
[TBL] [Abstract][Full Text] [Related]
8. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma.
Haldorsen IS; Popa M; Fonnes T; Brekke N; Kopperud R; Visser NC; Rygh CB; Pavlin T; Salvesen HB; McCormack E; Krakstad C
PLoS One; 2015; 10(8):e0135220. PubMed ID: 26252891
[TBL] [Abstract][Full Text] [Related]
11. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging.
Deroose CM; De A; Loening AM; Chow PL; Ray P; Chatziioannou AF; Gambhir SS
J Nucl Med; 2007 Feb; 48(2):295-303. PubMed ID: 17268028
[TBL] [Abstract][Full Text] [Related]
12. Dual-modality monitoring of tumor response to cyclophosphamide therapy in mice with bioluminescence imaging and small-animal positron emission tomography.
Ma X; Liu Z; Yang X; Gao Q; Zhu S; Qin C; Liu K; Zhang B; Han D; Wang F; Tian J
Mol Imaging; 2011 Aug; 10(4):278-83. PubMed ID: 21501569
[TBL] [Abstract][Full Text] [Related]
13. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
14. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
[TBL] [Abstract][Full Text] [Related]
15. A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model.
Fu Y; Ong LC; Ranganath SH; Zheng L; Kee I; Zhan W; Yu S; Chow PK; Wang CH
PLoS One; 2016; 11(2):e0148123. PubMed ID: 26844770
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
17. Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.
Karroum O; Mignion L; Kengen J; Karmani L; Levêque P; Danhier P; Magat J; Bol A; Labar D; Grégoire V; Bouzin C; Feron O; Gallez B; Jordan BF
Contrast Media Mol Imaging; 2013; 8(3):274-80. PubMed ID: 23606431
[TBL] [Abstract][Full Text] [Related]
18. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
[TBL] [Abstract][Full Text] [Related]
19. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
[TBL] [Abstract][Full Text] [Related]
20. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
